(VIANEWS) – The NASDAQ ended the session with Horizon Therapeutics rising 6.48% to $97.08 on Tuesday, following the last session’s downward trend. NASDAQ slid 0.96% to $13,619.63, after three successive sessions in a row of gains, on what was a somewhat negative trend exchanging session today.
Today’s last reported volume for Horizon Therapeutics is 2391930, 48.38% above its average volume of 1611940.
Horizon Therapeutics’s last close was $91.17, 24.37% below its 52-week high of $120.54.
Horizon Therapeutics’s Sales
Horizon Therapeutics’s sales growth is 85.7% for the present quarter and 27.5% for the next. The company’s growth estimates for the ongoing quarter is a negative 11.5% and positive 10.2% for the next.
Horizon Therapeutics’s Revenue
Year-on-year quarterly revenue growth grew by 79.9%, now sitting on 2.56B for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
Horizon Therapeutics’s stock is considered to be overbought (>=80).
Horizon Therapeutics’s Stock Yearly Top and Bottom Value
Horizon Therapeutics’s stock is valued at $97.08 at 16:21 EST, way under its 52-week high of $120.54 and way above its 52-week low of $66.41.
Horizon Therapeutics’s Moving Average
Horizon Therapeutics’s value is way under its 50-day moving average of $109.80 and under its 200-day moving average of $100.05.
More news about Horizon Therapeutics (HZNP).